TrialLancet (London, England)2020

Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.

Jessica E Manning et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.